Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice. Here, we explore recent treatment updates in chronic lymphocytic leukemia (CLL) ...

(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...

Comparative clinical and molecular outcomes of first, second, and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A comprehensive Bayesian network meta-analysis. Hazard ratios ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...